Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

AZNASTRAZENECA PLC

NYSE · CIK 0000901832
Filer categoryLarge accelerated filer
Entity typeother
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts375

Identity from submissions API

NameASTRAZENECA PLC
CIK0000901832
TickersAZN
ExchangesNYSE
Entity typeother
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationX0 United Kingdom
Phone011 44 20 7304 5000
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • ZENECA GROUP PLC (1995-03-13T05:00:00.000Z → 1999-02-05T05:00:00.000Z)
Business address
1 FRANCIS CRICK AVENUE
CAMBRIDGE BIOMEDICAL CAMPUS
CAMBRIDGE
CB2 0AA
United Kingdom
X0
Mailing address
1 FRANCIS CRICK AVENUE
CAMBRIDGE BIOMEDICAL CAMPUS
CAMBRIDGE
CB2 0AA
United Kingdom
X0

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

2062 filing rows loaded from submissions recent; extra archives: CIK0000901832-submissions-001.json (1061 filings, 1995-03-13 to 2019-06-29).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 6-K BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU 0001654954-26-009815 001-11960 261555392 34 68317
2026-11-16 6-K IMFINZI + EV APPROVED IN US IN BLADDER CANCER 0001654954-26-009811 001-11960 261555377 34 52154
2026-11-16 6-K KLYGEFA (GEFURULIMAB) APPROVED IN THE US 0001654954-26-009808 001-11960 261555350 34 43570
2026-11-16 6-K KLYGEFA (GEFURULIMAB) APPROVED IN THE EU 0001654954-26-009804 001-11960 261555281 34 43256
2026-11-10 4 PRIMARY DOCUMENT 0002122411-26-000003 5466
2026-11-02 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-009359 001-11960 261510450 34 34957
2026-11-02 6-K TOTAL VOTING RIGHTS 0001654954-26-009357 001-11960 261510412 34 17461
2026-10-30 6-K 3RD QUARTER RESULTS 0001654954-26-009256 001-11960 261504437 34 1666398
2026-10-27 6-K ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC 0001654954-26-009155 001-11960 261487292 34 70673
2026-10-22 6-K ULTOMIRIS APPROVED IN US IN IGAN 0001654954-26-009093 001-11960 261477204 34 52408
2026-10-08 4 PRIMARY DOCUMENT 0002122411-26-000002 5464
2026-10-05 6-K ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT 0001654954-26-008783 001-11960 261438787 34 22101
2026-10-02 6-K AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY 0001654954-26-008760 001-11960 261433401 34 35848
2026-10-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-008741 001-11960 261429771 34 36928
2026-10-01 6-K TOTAL VOTING RIGHTS 0001654954-26-008739 001-11960 261429719 34 20278
2026-09-29 6-K ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT 0001654954-26-008615 001-11960 261419064 34 32627
2026-09-23 6-K TRIXEO APPROVED IN EU FOR ASTHMA 0001654954-26-008520 001-11960 261398127 34 42423
2026-09-21 6-K KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP 0001654954-26-008478 001-11960 261392263 34 42167
2026-09-21 6-K ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC 0001654954-26-008476 001-11960 261392251 34 61321
2026-09-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008438 001-11960 261388678 34 49393
2026-09-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008369 001-11960 261379508 34 46286
2026-09-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008367 001-11960 261379388 34 46794
2026-09-14 6-K UPDATE ON SERENA-4 PHASE III TRIAL 0001654954-26-008323 001-11960 261375818 34 44851
2026-09-11 4 OWNERSHIP DOCUMENT 0001104659-26-107055 7668
2026-09-08 6-K IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG 0001654954-26-008172 001-11960 261363563 34 51636
2026-09-08 6-K ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER 0001654954-26-008150 001-11960 261363305 34 51318
2026-09-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-008042 001-11960 261349449 34 40189
2026-09-01 6-K TOTAL VOTING RIGHTS 0001654954-26-008040 001-11960 261349366 34 18774
2026-09-01 6-K ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING 0001654954-26-007992 001-11960 261348531 34 35310
2026-09-01 6-K ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC 0001654954-26-007990 001-11960 261348523 34 64359
2026-09-01 6-K DIRECTORATE CHANGE 0001654954-26-007988 001-11960 261348512 34 24339
2026-09-01 6-K ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY 0001654954-26-007986 001-11960 261348506 34 38691
2026-09-01 6-K TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG 0001654954-26-007983 001-11960 261348500 34 57189
2026-08-27 6-K TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS 0001654954-26-007894 001-11960 261324999 34 59555
2026-08-25 6-K ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING 0001654954-26-007840 001-11960 261312359 34 23917
2026-08-19 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007742 001-11960 261293081 34 47741
2026-08-17 6-K ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER 0001654954-26-007681 001-11960 261284757 34 65794
2026-08-17 6-K UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL 0001654954-26-007679 001-11960 261284753 34 33825
2026-08-17 6-K TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG 0001654954-26-007677 001-11960 261284746 34 60385
2026-08-07 4 PRIMARY DOCUMENT 0002122411-26-000001 5391
2026-08-03 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-007169 001-11960 261230993 34 34901
2026-08-03 6-K TOTAL VOTING RIGHTS 0001654954-26-007166 001-11960 261230959 34 19318
2026-07-31 6-K DATROWAY APPROVED IN EU FOR TNBC 0001654954-26-007050 001-11960 261225364 34 60233
2026-07-27 6-K FORM 6-K 0001104659-26-086846 001-11960 261202850 34 13685519 1 1
2026-07-27 6-K UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA 0001654954-26-006897 001-11960 261202802 34 58626
2026-07-27 6-K SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS 0001654954-26-006895 001-11960 261202785 34 53086
2026-07-23 6-K ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER 0001654954-26-006803 001-11960 261195084 34 53779
2026-07-14 6-K ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR 0001654954-26-006637 001-11960 261172504 34 41905
2026-07-09 6-K UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL 0001654954-26-006554 001-11960 261163934 34 40708
2026-07-08 4 OWNERSHIP DOCUMENT 0001104659-26-081807 5618
2026-07-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-006430 001-11960 261143126 34 38870
2026-07-01 6-K TOTAL VOTING RIGHTS 0001654954-26-006427 001-11960 261143106 34 17922
2026-06-29 11-K FORM 11-K 0001683168-26-005159 001-11960 261134856 34 2734731 1 1
2026-06-29 6-K ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS 0001654954-26-006251 001-11960 261131229 34 64333
2026-06-29 6-K DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC 0001654954-26-006239 001-11960 261131150 34 56729
2026-06-16 4 OWNERSHIP DOCUMENT 0001104659-26-074570 5617
2026-06-15 6-K TRUQAP APPROVED IN US FOR PROSTATE CANCER 0001654954-26-005964 001-11960 261089002 34 47396
2026-06-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING 0001654954-26-005587 001-11960 261047839 34 40730
2026-06-01 6-K TOTAL VOTING RIGHTS 0001654954-26-005586 001-11960 261047833 34 19612
2026-05-29 6-K IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER 0001654954-26-005498 001-11960 261038964 34 52644
2026-05-28 25-NSE xslF25X02/primary_doc.xml 0000876661-26-000484 001-11960 261033256 34 3791
2026-05-27 6-K US FDA DECISION DATE ON CAMIZESTRANT EXTENDED 0001654954-26-005381 001-11960 261022057 34 47075
2026-05-26 6-K DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC 0001654954-26-005309 001-11960 261015925 34 61824
2026-05-26 6-K ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS 0001654954-26-005306 001-11960 261015913 34 68157
2026-05-26 6-K CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU 0001654954-26-005303 001-11960 261015898 34 50900
2026-05-22 4 OWNERSHIP DOCUMENT 0001104659-26-065693 5568
2026-05-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005049 001-11960 26991217 34 46218
2026-05-18 6-K BAXFENDY APPROVED IN THE US FOR HYPERTENSION 0001654954-26-005044 001-11960 26991128 34 56128
2026-05-18 6-K ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS 0001654954-26-005038 001-11960 26991097 34 79471
2026-05-14 6-K IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER 0001654954-26-004836 001-11960 26975832 34 52629
2026-05-08 4 OWNERSHIP DOCUMENT 0001104659-26-057906 7498
2026-05-01 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES 0001654954-26-004247 001-11960 26929722 34 43223
2026-05-01 6-K FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER 0001654954-26-004229 001-11960 26929154 34 53217
2026-05-01 6-K FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER 0001654954-26-004226 001-11960 26929135 34 47610
2026-04-29 6-K 1ST QUARTER RESULTS 0001654954-26-004047 001-11960 26910533 34 1306144
2026-04-28 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-000022 005-55247 26905011 34 7683
2026-04-28 6-K BREZTRI APPROVED IN THE US FOR ASTHMA 0001654954-26-003979 001-11960 26903150 34 43431
2026-04-27 6-K SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US 0001654954-26-003936 001-11960 26896427 34 62818
2026-04-23 6-K DIRECTORATE CHANGE 0001654954-26-003818 001-11960 26885401 34 19580
2026-04-21 6-K I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT 0001654954-26-003757 001-11960 26876667 34 45808
2026-04-20 6-K THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD 0001654954-26-003703 001-11960 26873336 34 48096
2026-04-09 6-K RESULT OF AGM 0001654954-26-003374 001-11960 26850724 34 135423
2026-04-08 25-NSE xslF25X02/primary_doc.xml 0000876661-26-000343 001-11960 26847566 34 3810
2026-04-02 6-K IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER 0001654954-26-003206 001-11960 26830964 34 57911
2026-04-01 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES 0001654954-26-003157 001-11960 26825447 34 42290
2026-03-31 6-K EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS 0001654954-26-003013 001-11960 26817060 34 56279
2026-03-27 6-K TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS 0001654954-26-002860 001-11960 26801154 34 52068
2026-03-20 6-K NOTIFICATION OF ADMISSION OF SHARES 0001654954-26-002523 001-11960 26776147 34 40108
2026-03-19 3 OWNERSHIP DOCUMENT 0001104659-26-032249 8536
2026-03-16 6-K IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER 0001654954-26-002272 001-11960 26754658 34 58776
2026-03-10 6-K NOTICE OF AGM 0001654954-26-002077 001-11960 26737286 34 30294
2026-03-10 6-K FORM 6-K 0001104659-26-025559 001-11960 26737246 34 6341592
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001966 001-11960 26728519 34 46656
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001963 001-11960 26728480 34 70541
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001961 001-11960 26728470 34 72719
2026-03-04 CERT NYSE CERTIFICATION 0000876661-26-000201 001-11960 26719051 34 177030
2026-03-03 8-A12B FORM 8-A12B 0001104659-26-022824 001-11960 26713776 34 23292
2026-03-02 6-K FORM 6-K 0001104659-26-022240 001-11960 26707494 34 916240
2026-03-02 6-K TOTAL VOTING RIGHTS 0001654954-26-001728 001-11960 26705408 34 19646
2026-02-27 424B2 424B2 0001104659-26-021545 333-278067 26699623 33 1052004 1 1
2026-02-26 6-K ASTRAZENECA PRICES A $2BN BOND OFFERING 0001654954-26-001589 001-11960 26681970 34 24351
2026-02-26 FWP FWP 0001104659-26-019812 333-278067 26680864 34 38468
2026-02-25 6-K FILING OF FORM 20-F WITH SEC 0001654954-26-001536 001-11960 26675295 34 18386
2026-02-25 424B2 424B2 0001104659-26-019420 333-278067 26674335 33 848482
2026-02-24 IRANNOTICE IRANNOTICE 0001104659-26-019141 001-11960 26671895 34 6578
2026-02-24 20-F 20-F 0001104659-26-019130 001-11960 26671828 34 127817049 1 1
2026-02-24 6-K FORM 6-K 0001104659-26-019110 001-11960 26671556 34 24060371
2026-02-24 6-K ANNUAL FINANCIAL REPORT 0001654954-26-001483 001-11960 26667404 34 21534
2026-02-24 6-K DIRECTORATE CHANGE 0001654954-26-001481 001-11960 26667398 34 21967
2026-02-20 6-K FIXED-DURATION CALQUENCE COMBO APPROVED IN US 0001654954-26-001409 001-11960 26656623 34 44133
2026-02-10 6-K FINAL RESULTS 0001654954-26-001073 001-11960 26614494 34 1707501
2026-02-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-011303 9872
2026-02-06 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-26-011298 42402
2026-02-03 6-K UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION 0001654954-26-000857 001-11960 26590118 34 52426
2026-02-02 S-8 FORM S-8 0001104659-26-009284 333-293157 26592318 33 1357766 1 1
2026-02-02 6-K TOTAL VOTING RIGHTS 0001654954-26-000824 001-11960 26586876 34 19872
2026-02-02 6-K IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER 0001654954-26-000795 001-11960 26585789 34 61248
2026-02-02 6-K ASTRAZENECA BEGINS TRADING ON NYSE 0001654954-26-000792 001-11960 26585717 34 23213
2026-01-30 25 FORM 25 0001104659-26-008613 001-11960 26583250 34 19655
2026-01-30 6-K ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC 0001654954-26-000730 001-11960 26580386 34 32710
2026-01-29 6-K ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 0001654954-26-000688 001-11960 26574894 34 26133
2026-01-22 CERT NYSE CERTIFICATION 0000876661-26-000055 001-11960 26552047 34 181611
2026-01-22 8-A12B 8-A12B 0001104659-26-005799 001-11960 26551955 34 47747
2026-01-22 CERT NYSE CERTIFICATION 0000876661-26-000054 001-11960 26551697 34 164661
2026-01-22 8-A12B 8-A12B 0001104659-26-005772 001-11960 26551524 34 13416
2026-01-20 6-K ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE 0001654954-26-000464 001-11960 26541130 34 21267
2026-01-08 6-K AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON 0001654954-26-000153 001-11960 26517270 34 19370
2026-01-02 6-K TOTAL VOTING RIGHTS 0001654954-26-000027 001-11960 26501268 34 20449
2025-12-22 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-014171 001-11960 251589511 34 45879
2025-12-22 6-K ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC 0001654954-25-014166 001-11960 251589444 34 62170
2025-12-22 6-K UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB 0001654954-25-014164 001-11960 251589414 34 40386
2025-12-19 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-014136 001-11960 251585151 34 62369
2025-12-16 6-K SUBCUTANEOUS SAPHNELO APPROVED IN EU 0001654954-25-013974 001-11960 251573319 34 57420
2025-12-16 6-K ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC 0001654954-25-013970 001-11960 251573309 34 66439
2025-12-04 6-K HOLDING(S) IN COMPANY 0001654954-25-013678 001-11960 251548931 34 78690
2025-12-01 6-K BLOCK LISTING INTERIM REVIEW 0001654954-25-013569 001-11960 251538325 34 32613
2025-12-01 6-K TOTAL VOTING RIGHTS 0001654954-25-013567 001-11960 251538307 34 20258
2025-11-26 6-K IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER 0001654954-25-013450 001-11960 251523793 34 62395
2025-11-24 6-K ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND 0001654954-25-013401 001-11960 251509546 34 25425
2025-11-20 6-K KOSELUGO (SELUMETINIB) APPROVED IN THE US 0001654954-25-013317 001-11960 251501122 34 42305
2025-11-17 6-K HOLDING(S) IN COMPANY 0001654954-25-013129 001-11960 251490278 34 81049
2025-11-14 25-NSE xslF25X02/primary_doc.xml 0001354457-25-001137 001-11960 251486126 34 3247
2025-11-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-013043 001-11960 251482174 34 44836
2025-11-12 144 xsl144X01/primary_doc.xml 0001950047-25-008803 001-11960 251474504 33 4968
2025-11-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-012757 001-11960 251465253 34 40170
2025-11-06 6-K 9M AND Q3 2025 RESULTS 0001654954-25-012630 001-11960 251456192 34 1688203
2025-11-03 6-K RESULT OF GENERAL MEETING 0001654954-25-012502 001-11960 251443233 34 35044
2025-11-03 6-K TOTAL VOTING RIGHTS 0001654954-25-012498 001-11960 251443198 34 20401
2025-11-03 6-K FORM 6-K 0001104659-25-105425 001-11960 251443042 34 21376965
2025-10-28 6-K DIRECTOR DECLARATION 0001654954-25-012271 001-11960 251421889 34 17761
2025-10-28 6-K KOSELUGO (SELUMETINIB) APPROVED IN THE EU 0001654954-25-012262 001-11960 251421489 34 41333
2025-10-22 6-K TEZSPIRE APPROVED IN EU FOR CRSWNP 0001654954-25-012040 001-11960 251408640 34 54418
2025-10-20 6-K US FDA APPROVES TEZSPIRE IN CRSWNP 0001654954-25-011951 001-11960 251402303 34 62408
2025-10-20 6-K POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO 0001654954-25-011943 001-11960 251402283 34 57209
2025-10-14 6-K AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES 0001654954-25-011688 001-11960 251389245 34 26312
2025-10-07 6-K BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL 0001654954-25-011529 001-11960 251378213 34 51408
2025-10-06 6-K DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 0001654954-25-011461 001-11960 251375606 34 57058
2025-10-01 6-K TOTAL VOTING RIGHTS 0001654954-25-011310 001-11960 251362895 34 19997
2025-09-29 6-K ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 0001654954-25-011177 001-11960 251352083 34 62865
2025-09-29 6-K AZN HARMONISES LISTING STRUCTURE 0001654954-25-011175 001-11960 251352063 34 30884
2025-09-29 6-K 6-K 0001104659-25-094039 001-11960 251351991 34 737560
2025-09-25 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-011107 001-11960 251342488 34 41372
2025-09-22 6-K KOSELUGO RECOMMENDED FOR EU APPROVAL 0001654954-25-010969 001-11960 251328438 34 41580
2025-09-22 6-K TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP 0001654954-25-010967 001-11960 251328433 34 58862
2025-09-17 6-K SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC 0001654954-25-010847 001-11960 251318795 34 51228
2025-09-17 6-K UPDATE ON RESOLUTE PHASE III TRIAL 0001654954-25-010845 001-11960 251318780 34 41684
2025-09-02 6-K TOTAL VOTING RIGHTS 0001654954-25-010235 001-11960 251282853 34 20246
2025-08-28 6-K HOLDING(S) IN COMPANY 0001654954-25-010131 001-11960 251269183 34 17912
2025-08-26 6-K HOLDING(S) IN COMPANY 0001654954-25-010040 001-11960 251255476 34 77930
2025-08-21 6-K HOLDING(S) IN COMPANY 0001654954-25-009884 001-11960 251239088 34 67894
2025-08-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-009748 001-11960 251226891 34 46056
2025-08-15 6-K HOLDING(S) IN COMPANY 0001654954-25-009692 001-11960 251222935 34 69142
2025-08-12 6-K HOLDING(S) IN COMPANY 0001654954-25-009396 001-11960 251204997 34 76082
2025-08-01 6-K TOTAL VOTING RIGHTS 0001654954-25-008838 001-11960 251175618 34 17627
2025-07-29 6-K FORM 6-K 0001104659-25-071432 001-11960 251157612 34 12594635 1 1
2025-07-24 6-K GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS 0001654954-25-008413 001-11960 251145770 34 35640
2025-07-22 6-K ASTRAZENECA PLANS TO INVEST $50BN IN THE US 0001654954-25-008260 001-11960 251138632 34 28300
2025-07-16 6-K UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS 0001654954-25-008111 001-11960 251126135 34 37091
2025-07-14 6-K BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL 0001654954-25-008010 001-11960 251120417 34 49907
2025-07-07 6-K IMFINZI APPROVED IN THE EU FOR BLADDER CANCER 0001654954-25-007785 001-11960 251106942 34 46977
2025-07-01 6-K TOTAL VOTING RIGHTS 0001654954-25-007604 001-11960 251094864 34 20389
2025-06-26 11-K FORM 11-K 0001683168-25-004771 001-11960 251079165 34 240907
2025-06-24 6-K DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER 0001654954-25-007315 001-11960 251066643 34 62966
2025-06-13 6-K ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC 0001654954-25-006914 001-11960 251045311 34 22370
2025-06-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-006868 001-11960 251042017 34 40734
2025-06-06 6-K FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL 0001654954-25-006655 001-11960 251028907 34 42328
2025-06-02 6-K BLOCK LISTING INTERIM REVIEW 0001654954-25-006418 001-11960 251014028 34 30909
2025-06-02 6-K TOTAL VOTING RIGHTS 0001654954-25-006414 001-11960 251013984 34 17993
2025-05-27 6-K IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER 0001654954-25-006101 001-11960 25984098 34 48703
2025-05-23 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-006059 001-11960 25979411 34 43255
2025-05-21 6-K DIRECTOR DECLARATION 0001654954-25-005972 001-11960 25971182 34 18219
2025-05-20 6-K ACQUISITION OF ESOBIOTEC COMPLETED 0001654954-25-005901 001-11960 25966152 34 25946
2025-05-09 6-K IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER 0001654954-25-005331 001-11960 25928971 34 44769
2025-05-07 6-K ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER 0001654954-25-005175 001-11960 25919677 34 57503
2025-05-06 6-K CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL 0001654954-25-005099 001-11960 25915608 34 40262
2025-05-02 6-K BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS 0001654954-25-005021 001-11960 25905872 34 38873
2025-05-01 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-004975 001-11960 25901508 34 48981
2025-05-01 6-K TOTAL VOTING RIGHTS 0001654954-25-004956 001-11960 25900795 34 21217
2025-04-29 6-K FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL 0001654954-25-004745 001-11960 25885161 34 43329
2025-04-29 6-K UPDATE ON CAPITELLO-280 PHASE III TRIAL 0001654954-25-004742 001-11960 25884845 34 36979
2025-04-29 6-K 1ST QUARTER RESULTS 0001654954-25-004737 001-11960 25884755 34 1323071
2025-04-23 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001438 005-55247 25863155 34 11526
2025-04-22 6-K ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC 0001654954-25-004504 001-11960 25854910 34 61275
2025-04-11 6-K RESULT OF AGM 0001654954-25-004150 001-11960 25830970 34 135784
2025-04-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-033481 9519
2025-04-04 6-K IMFINZI APPROVED IN EU FOR AEGEAN 0001654954-25-003896 001-11960 25812023 34 56821
2025-04-04 6-K ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER 0001654954-25-003894 001-11960 25811935 34 67854
2025-04-01 6-K TOTAL VOTING RIGHTS 0001654954-25-003772 001-11960 25798105 34 19822
2025-03-31 6-K CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL 0001654954-25-003590 001-11960 25788881 34 44561
2025-03-31 6-K IMFINZI APPROVED IN THE US FOR BLADDER CANCER 0001654954-25-003589 001-11960 25788826 34 53425
2025-03-21 6-K AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING 0001654954-25-003128 001-11960 25758611 34 23326
2025-03-17 6-K ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT 0001654954-25-002841 001-11960 25742354 34 35745
2025-03-17 6-K IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC 0001654954-25-002839 001-11960 25742344 34 54524
2025-03-17 6-K ASTRAZENECA TO ACQUIRE ESOBIOTEC 0001654954-25-002837 001-11960 25742336 34 29878
2025-03-12 6-K HOLDING(S) IN COMPANY 0001654954-25-002669 001-11960 25731478 34 75358
2025-03-07 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-002424 001-11960 25718067 34 46890
2025-03-07 6-K NOTICE OF AGM 0001654954-25-002413 001-11960 25717559 34 27050
2025-03-07 6-K IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER 0001654954-25-002412 001-11960 25717557 34 60646
2025-03-07 6-K FORM 6-K 0001104659-25-021517 001-11960 25717511 34 6060551
2025-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-002350 001-11960 25714105 34 115910
2025-03-05 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-002308 001-11960 25709332 34 71846
2025-03-03 6-K TOTAL VOTING RIGHTS 0001654954-25-002199 001-11960 25694859 34 19892
2025-03-03 6-K IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN 0001654954-25-002166 001-11960 25693507 34 55073
2025-02-28 6-K ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER 0001654954-25-002102 001-11960 25683266 34 69253
2025-02-26 6-K CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER 0001654954-25-001920 001-11960 25665931 34 47026
2025-02-19 6-K FILING OF FORM 20-F WITH SEC 0001654954-25-001661 001-11960 25637139 34 18546
2025-02-18 IRANNOTICE IRANNOTICE 0001104659-25-014758 001-11960 25634900 34 6915
2025-02-18 20-F FORM 20-F 0001104659-25-014750 001-11960 25634866 34 147240282 1 1
2025-02-18 6-K FORM 6-K 0001104659-25-014732 001-11960 25634750 34 24533305
2025-02-18 6-K HOLDING(S) IN COMPANY 0001654954-25-001625 001-11960 25633304 34 66742
2025-02-18 6-K ANNUAL FINANCIAL REPORT 0001654954-25-001619 001-11960 25632784 34 21991
2025-02-18 6-K DIRECTORATE CHANGE 0001654954-25-001614 001-11960 25632757 34 25555
2025-02-06 6-K FINAL RESULTS 0001654954-25-001189 001-11960 25595803 34 1754956
2025-02-05 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000324 333-284374 25595215 33 1892
2025-02-03 6-K TOTAL VOTING RIGHTS 0001654954-25-001087 001-11960 25581617 34 19788
2025-02-03 6-K IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC 0001654954-25-001005 001-11960 25580494 34 56157
2025-01-28 6-K ENHERTU APPROVED IN US FOR BREAST CANCER POST ET 0001654954-25-000846 001-11960 25561246 34 69661
2025-01-24 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-25-005814 14466
2025-01-21 F-6 e664152_f6-az.htm 0001193805-25-000067 333-284374 25541411 33 472128
2025-01-21 6-K DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER 0001654954-25-000565 001-11960 25540382 34 51233
2025-01-17 6-K CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL 0001654954-25-000518 001-11960 25537003 34 47063
2025-01-02 6-K TOTAL VOTING RIGHTS 0001654954-25-000031 001-11960 25500585 34 19488
2024-12-26 6-K DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU 0001654954-24-015891 001-11960 241578726 34 42667
2024-12-23 6-K TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL 0001654954-24-015839 001-11960 241571683 34 52215
2024-12-16 6-K DIRECTORATE CHANGE 0001654954-24-015567 001-11960 241550399 34 27654
2024-12-05 6-K IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC 0001654954-24-015165 001-11960 241527683 34 55153
2024-12-04 6-K ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL 0001654954-24-015151 001-11960 241525044 34 22562
2024-12-02 6-K BLOCK LISTING INTERIM REVIEW 0001654954-24-015049 001-11960 241517727 34 34455
2024-12-02 6-K TOTAL VOTING RIGHTS 0001654954-24-015048 001-11960 241517715 34 21197
2024-11-25 6-K TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER 0001654954-24-014843 001-11960 241491886 34 41767
2024-11-20 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-014697 001-11960 241478827 34 44444
2024-11-18 6-K TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA 0001654954-24-014570 001-11960 241469683 34 52900
2024-11-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-014517 001-11960 241466018 34 46679
2024-11-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-014508 001-11960 241465818 34 48602
2024-11-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-014235 001-11960 241452648 34 48216
2024-11-12 6-K ASTRAZENECA INVESTS $3.5 BILLION IN US 0001654954-24-014095 001-11960 241443437 34 25182
2024-11-12 6-K KOMET PHASE III TRIAL MET PRIMARY ENDPOINT 0001654954-24-014093 001-11960 241443406 34 44541
2024-11-12 6-K 9M AND Q3 2024 RESULTS 0001654954-24-014089 001-11960 241443352 34 1796492
2024-11-12 6-K DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN 0001654954-24-014084 001-11960 241443234 34 56797
2024-11-08 6-K TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS 0001654954-24-013972 001-11960 241438199 34 60267
2024-11-01 6-K TOTAL VOTING RIGHTS 0001654954-24-013617 001-11960 241417931 34 19964
2024-10-30 6-K AZN CHINA PRESIDENT UNDER INVESTIGATION 0001654954-24-013471 001-11960 241407735 34 18955
2024-10-28 SC 13G SC 13G 0001104659-24-111584 62629
2024-10-21 6-K FORM 6-K 0001654954-24-013146 001-11960 241382220 34 44055
2024-10-11 SC 13G SC 13G 0001104659-24-107836 55659
2024-10-07 6-K ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET 0001654954-24-012726 001-11960 241356110 34 31791
2024-10-01 6-K TOTAL VOTING RIGHTS 0001654954-24-012560 001-11960 241341774 34 19668
2024-09-26 6-K TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER 0001654954-24-012321 001-11960 241326153 34 51360
2024-09-23 6-K FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA 0001654954-24-012148 001-11960 241314593 34 49051
2024-09-23 6-K FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 0001654954-24-012146 001-11960 241314577 34 52038
2024-09-20 6-K FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US 0001654954-24-012136 001-11960 241312769 34 37719
2024-09-18 6-K FASENRA EGPA US FDA APPROVAL 0001654954-24-012038 001-11960 241306151 34 56484
2024-09-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-011899 001-11960 241296779 34 42324
2024-09-03 6-K TOTAL VOTING RIGHTS 0001654954-24-011365 001-11960 241271779 34 18992
2024-08-16 6-K IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER 0001654954-24-010777 001-11960 241214072 34 55359
2024-08-01 6-K TOTAL VOTING RIGHTS 0001654954-24-009768 001-11960 241164855 34 19745
2024-07-30 6-K ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING 0001654954-24-009571 001-11960 241154311 34 24014
2024-07-29 6-K CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS 0001654954-24-009496 001-11960 241148655 34 39844
2024-07-26 6-K ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER 0001654954-24-009439 001-11960 241143520 34 49581
2024-07-25 6-K FORM 6K 0001104659-24-082531 001-11960 241140159 34 14086577 1 1
2024-07-15 6-K ACQUISITION OF AMOLYT PHARMA COMPLETED 0001654954-24-008909 001-11960 241115809 34 32400
2024-07-01 6-K TOTAL VOTING RIGHTS 0001654954-24-008432 001-11960 241088647 34 19230
2024-07-01 6-K LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL 0001654954-24-008387 001-11960 241087977 34 61205
2024-06-26 11-K ANNUAL REPORT 0001683168-24-004498 001-11960 241074360 34 209946
2024-06-25 6-K UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL 0001654954-24-008130 001-11960 241066102 34 52108
2024-06-25 6-K IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER 0001654954-24-008126 001-11960 241066094 34 46635
2024-06-18 6-K UPDATE ON CAPITELLO-290 PHASE III TRIAL 0001654954-24-007869 001-11960 241050143 34 46245
2024-06-17 6-K IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER 0001654954-24-007805 001-11960 241046903 34 52138
2024-06-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-007632 001-11960 241037676 34 47161
2024-06-04 6-K FORM 6-K 0001104659-24-068260 001-11960 241018414 34 25649
2024-06-04 25-NSE xslF25X02/primary_doc.xml 0001354457-24-000385 001-11960 241016302 34 3216
2024-06-03 6-K BLOCK LISTING INTERIM REVIEW 0001654954-24-007202 001-11960 241012362 34 32392
2024-06-03 6-K TOTAL VOTING RIGHTS 0001654954-24-007199 001-11960 241012345 34 19979
2024-06-03 6-K TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU 0001654954-24-007172 001-11960 241011936 34 50426
2024-05-28 6-K DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER 0001654954-24-006926 001-11960 24986194 34 50234
2024-05-21 6-K ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 0001654954-24-006698 001-11960 24966776 34 39256
2024-05-20 6-K ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE 0001654954-24-006631 001-11960 24962302 34 23938
2024-05-16 6-K SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT 0001654954-24-006451 001-11960 24953526 34 34032
2024-05-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-006324 001-11960 24947912 34 45396
2024-05-07 6-K ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT 0001654954-24-005658 001-11960 24919620 34 26851
2024-05-02 6-K CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL 0001654954-24-005422 001-11960 24905144 34 41908
2024-05-01 6-K TOTAL VOTING RIGHTS 0001654954-24-005359 001-11960 24900827 34 18741
2024-04-29 6-K TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL 0001654954-24-005107 001-11960 24886585 34 66185
2024-04-29 6-K ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW 0001654954-24-005105 001-11960 24886524 34 56475
2024-04-25 6-K 1ST QUARTER RESULTS 0001654954-24-004975 001-11960 24872745 34 1367259
2024-04-11 6-K RESULT OF AGM 0001654954-24-004501 001-11960 24837877 34 140563
2024-04-11 6-K ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% 0001654954-24-004470 001-11960 24837098 34 22554
2024-04-08 6-K ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS 0001654954-24-004314 001-11960 24828037 34 69279
2024-04-05 6-K IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC 0001654954-24-004274 001-11960 24824701 34 52721
2024-04-02 6-K TOTAL VOTING RIGHTS 0001654954-24-004141 001-11960 24813159 34 20286
2024-04-02 6-K VOYDEYA APPROVED IN US 0001654954-24-004088 001-11960 24812332 34 48597
2024-04-02 6-K FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER 0001654954-24-004084 001-11960 24812252 34 46251
2024-03-25 6-K ULTOMIRIS APPROVED IN THE US FOR NMOSD 0001654954-24-003566 001-11960 24776882 34 55187
2024-03-19 DFAN14A DFAN14A 0001104659-24-036230 2907659
2024-03-19 F-3ASR F-3ASR 0001104659-24-036178 333-278067 24763902 33 971941
2024-03-19 6-K FORM 6-K 0001104659-24-035786 001-11960 24760981 34 34208
2024-03-14 6-K ASTRAZENECA TO ACQUIRE AMOLYT 0001654954-24-003100 001-11960 24747909 34 39205
2024-03-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-002957 001-11960 24740187 34 49250
2024-03-07 6-K FORM 6-K 0001104659-24-031683 001-11960 24728065 34 5602200
2024-03-07 6-K NOTICE OF AGM 0001654954-24-002749 001-11960 24728063 34 27080
2024-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-002690 001-11960 24724628 34 45296
2024-03-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-002688 001-11960 24724616 34 69623
2024-03-06 CERT AZN_8A_Cert_Notes.pdf 0001354457-24-000128 001-11960 24724369 34 280073
2024-03-05 8-A12B 8-A12B 0001104659-24-031066 001-11960 24721398 34 26000
2024-03-04 6-K EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC 0001654954-24-002518 001-11960 24712790 34 46647
2024-03-01 6-K TOTAL VOTING RIGHTS 0001654954-24-002477 001-11960 24707835 34 19837
2024-02-26 6-K FORM 6-K 0001104659-24-027496 001-11960 24678674 34 1449996
2024-02-26 6-K VOYDEYA RECOMMENDED FOR EU APPROVAL 0001654954-24-002155 001-11960 24673473 34 49413
2024-02-23 424B2 424B2 0001104659-24-027015 333-256406 24671220 33 960084
2024-02-22 6-K ASTRAZENECA PRICES A $5BN BOND OFFERING 0001654954-24-002042 001-11960 24662544 34 26576
2024-02-22 6-K FORM 6-K 0001104659-24-026359 001-11960 24662518 34 25358
2024-02-22 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-24-002028 001-11960 24662175 34 46543
2024-02-22 FWP FWP 0001104659-24-026163 333-256406 24661712 34 49055
2024-02-21 SC TO-T/A SC TO-T/A 0001104659-24-025822 29961
2024-02-21 424B2 424B2 0001104659-24-025819 333-256406 24656447 33 900411
2024-02-21 6-K FILING OF FORM 20-F WITH SEC 0001654954-24-001982 001-11960 24656290 34 19066
2024-02-20 S-8 FORM S-8 0001104659-24-025610 333-277197 24654943 33 176566
2024-02-20 IRANNOTICE IRANNOTICE 0001104659-24-025568 001-11960 24654066 34 7451
2024-02-20 20-F FORM 20-F 0001104659-24-025553 001-11960 24654013 34 140839360 1 1
2024-02-20 6-K FORM 6-K 0001104659-24-025540 001-11960 24653673 34 18449803
2024-02-20 6-K ANNUAL FINANCIAL REPORT 0001654954-24-001937 001-11960 24651167 34 25218
2024-02-20 SC TO-T/A SC TO-T/A 0001104659-24-025223 73208
2024-02-20 6-K FORM 6-K 0001104659-24-025224 001-11960 24650761 34 34508
2024-02-20 6-K ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX 0001654954-24-001914 001-11960 24650688 34 45816
2024-02-20 6-K TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER 0001654954-24-001908 001-11960 24650647 34 48760
2024-02-20 6-K FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC 0001654954-24-001903 001-11960 24650641 34 44768
2024-02-20 6-K TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER 0001654954-24-001899 001-11960 24650602 34 46070
2024-02-15 SC TO-T/A SC TO-T/A 0001104659-24-024104 33004
2024-02-12 SC 13G/A SC 13G/A 0001104659-24-013882 58087
2024-02-08 6-K FINAL RESULTS 0001654954-24-001467 001-11960 24606794 34 1917570
2024-02-01 6-K TOTAL VOTING RIGHTS 0001654954-24-001173 001-11960 24585423 34 19954
2024-01-24 SC 13G/A gb0009895292_012424.txt 0001086364-24-002650 005-55247 24557742 34 14201
2024-01-19 SC TO-T/A SC TO-T/A 0001104659-24-005033 43101
2024-01-19 6-K FORM 6-K 0001104659-24-005026 001-11960 24543807 34 24039
2024-01-11 SC TO-T/A SC TO-T/A 0001104659-24-003090 75647
2024-01-10 CORRESP filename1.htm 0001104659-24-003086 64882
2024-01-02 6-K TOTAL VOTING RIGHTS 0001654954-24-000032 001-11960 24500899 34 19431
2023-12-27 SC TO-T SC TO-T 0001104659-23-129493 5653434
2023-12-27 6-K ASTRAZENECA ACQUIRES GRACELL 0001654954-23-015982 001-11960 231514594 34 42196
2023-12-26 6-K FORM 6-K 0001104659-23-129281 001-11960 231514181 34 33933
2023-12-22 6-K WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL 0001654954-23-015901 001-11960 231507114 34 43472
2023-12-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-23-015521 001-11960 231485880 34 44898
2023-12-12 SC TO-C SC TO-C 0001104659-23-125421 93499
2023-12-12 6-K FORM 6-K 0001104659-23-125420 001-11960 231482051 34 43151
2023-12-12 6-K ASTRAZENECA TO ACQUIRE ICOSAVAX 0001654954-23-015390 001-11960 231479910 34 50767
2023-12-01 6-K BLOCK LISTING INTERIM REVIEW 0001654954-23-015044 001-11960 231458169 34 35700
2023-12-01 6-K TOTAL VOTING RIGHTS 0001654954-23-015043 001-11960 231458158 34 21476
2023-12-01 6-K DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS 0001654954-23-015010 001-11960 231457475 34 43041
2023-11-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-23-014734 001-11960 231435006 34 72838
2023-11-17 6-K TRUQAP APPROVED IN US FOR HR+ BREAST CANCER 0001654954-23-014510 001-11960 231416395 34 54414
2023-11-16 SC 13D/A SC 13D/A 0001104659-23-118991 48065
2023-11-14 25-NSE xslF25X02/primary_doc.xml 0001354457-23-000837 001-11960 231406594 34 3103
2023-11-14 6-K UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI 0001654954-23-014199 001-11960 231401465 34 48561
2023-11-13 144 xsl144X01/primary_doc.xml 0001104659-23-116769 001-11960 231395336 33 6705
2023-11-09 SC 13D SC 13D 0001104659-23-116366 96935
2023-11-09 6-K DIRECTOR DECLARATION 0001654954-23-013975 001-11960 231390498 34 21459
2023-11-09 6-K IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER 0001654954-23-013973 001-11960 231390478 34 56457
2023-11-09 6-K AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA 0001654954-23-013971 001-11960 231390463 34 26798
2023-11-09 6-K 9M AND Q3 2023 RESULTS 0001654954-23-013969 001-11960 231390442 34 1949503
2023-11-01 6-K TOTAL VOTING RIGHTS 0001654954-23-013666 001-11960 231367317 34 18924
2023-11-01 6-K ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS 0001654954-23-013630 001-11960 231366477 34 28280
2023-10-03 6-K ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS 0001654954-23-012523 001-11960 231301562 34 23543
2023-10-02 6-K TOTAL VOTING RIGHTS 0001654954-23-012469 001-11960 231298260 34 19979
2023-09-25 6-K DATO-DXD IMPROVED PFS IN BREAST CANCER 0001654954-23-012206 001-11960 231274363 34 47243
2023-09-20 6-K ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT 0001654954-23-012050 001-11960 231265285 34 21473
2023-09-15 6-K ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC 0001654954-23-011919 001-11960 231257115 34 56312
2023-09-11 6-K FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT 0001654954-23-011717 001-11960 231247111 34 49581
2023-09-06 6-K UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD 0001654954-23-011565 001-11960 231237824 34 49120
2023-09-01 6-K TOTAL VOTING RIGHTS 0001654954-23-011460 001-11960 231230997 34 18849
2023-08-16 25-NSE xslF25X02/primary_doc.xml 0001354457-23-000587 001-11960 231178300 34 3135
2023-08-01 6-K TOTAL VOTING RIGHTS 0001654954-23-009946 001-11960 231130547 34 20011
2023-07-28 6-K FORM 6K 0001104659-23-085104 001-11960 231120334 34 13871725 1 1
2023-07-28 6-K ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER 0001654954-23-009766 001-11960 231120121 34 26872
2023-07-17 6-K BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION 0001654954-23-009256 001-11960 231091296 34 53952
2023-07-03 6-K TOTAL VOTING RIGHTS 0001654954-23-008686 001-11960 231064540 34 19668
2023-07-03 6-K DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER 0001654954-23-008655 001-11960 231063734 34 48105
2023-06-28 11-K ANNUAL REPORT 0001683168-23-004490 001-11960 231053375 34 196950
2023-06-09 6-K NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION 0001654954-23-007833 001-11960 231003835 34 74697
2023-06-09 6-K ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS 0001654954-23-007832 001-11960 231003822 34 27028
2023-06-02 6-K IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS 0001654954-23-007542 001-11960 23987431 34 56634

Latest XBRL company facts

One latest value per concept from companyfacts (375 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
ifrs-full AccountingProfit AccountingProfit USD 12.40B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AccrualsClassifiedAsCurrent AccrualsClassifiedAsCurrent USD 7.26B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AccrualsClassifiedAsNoncurrent AccrualsClassifiedAsNoncurrent USD 85.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AcquisitionsThroughBusinessCombinationsOtherProvisions AcquisitionsThroughBusinessCombinationsOtherProvisions USD 50.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment USD 1.14B 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsBeforeTaxDefinedBenefitPlans ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsBeforeTaxDefinedBenefitPlans USD -74.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsBeforeTaxDefinedBenefitPlans ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsBeforeTaxDefinedBenefitPlans USD 220.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ActuarialGainsLossesArisingFromExperienceAdjustmentsBeforeTaxDefinedBenefitPlans ActuarialGainsLossesArisingFromExperienceAdjustmentsBeforeTaxDefinedBenefitPlans USD 59.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination USD 198.00M 2024-01-01 2024-06-30 2025 Q2 6-K 2025-07-29 0001104659-25-071432
ifrs-full AdjustedWeightedAverageShares AdjustedWeightedAverageShares shares 1.56B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForCurrentTaxOfPriorPeriod AdjustmentsForCurrentTaxOfPriorPeriod USD -60.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForDecreaseIncreaseInInventories AdjustmentsForDecreaseIncreaseInInventories USD -755.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables USD -1.73B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForDeferredTaxOfPriorPeriods AdjustmentsForDeferredTaxOfPriorPeriods USD -47.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss USD 5.73B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForFinanceIncomeCost AdjustmentsForFinanceIncomeCost USD -1.33B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates USD 776.00M 2021-01-01 2021-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment USD -13.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives USD -172.00M 2019-01-01 2019-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full AdjustmentsForSharebasedPayments AdjustmentsForSharebasedPayments USD 719.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod USD -7.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdjustmentsForUnrealisedForeignExchangeLossesGains AdjustmentsForUnrealisedForeignExchangeLossesGains USD 201.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans USD 5.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AllowanceAccountForCreditLossesOfFinancialAssets AllowanceAccountForCreditLossesOfFinancialAssets USD 59.00M 2022-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full AmortisationIntangibleAssetsOtherThanGoodwill AmortisationIntangibleAssetsOtherThanGoodwill USD 4.21B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AmountsPayableToTransfereeInRespectOfTransferredAssets AmountsPayableToTransfereeInRespectOfTransferredAssets USD 1.59B 2022-06-30 2022 Q2 6-K 2022-07-29 0001104659-22-083922
ifrs-full ApplicableTaxRate ApplicableTaxRate pure 0.25 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Assets Assets USD 114.07B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AverageEffectiveTaxRate AverageEffectiveTaxRate pure 0.18 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full AverageNumberOfEmployees AverageNumberOfEmployees employee 95,100 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full BalancesWithBanks BalancesWithBanks USD 5.80B 2023-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full BankOverdraftsClassifiedAsCashEquivalents BankOverdraftsClassifiedAsCashEquivalents USD 13.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full BasicEarningsLossPerShare BasicEarningsLossPerShare USD/shares 6.6 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Borrowings Borrowings USD 29.62B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full BorrowingsInterestRate BorrowingsInterestRate pure 0.03 2019-01-01 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full CapitalRedemptionReserve CapitalRedemptionReserve USD 153.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Cash Cash USD 1.33B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashAndCashEquivalents CashAndCashEquivalents USD 5.71B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets USD 1.07B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition USD 5.70B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashCollateralPledgedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities CashCollateralPledgedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities USD 465.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashCollateralReceivedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets CashCollateralReceivedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets USD 465.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsFromUsedInFinancingActivities CashFlowsFromUsedInFinancingActivities USD -7.54B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings USD 364.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsFromUsedInInvestingActivities CashFlowsFromUsedInInvestingActivities USD -6.81B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsFromUsedInOperatingActivities CashFlowsFromUsedInOperatingActivities USD 14.57B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsFromUsedInOperations CashFlowsFromUsedInOperations USD 18.74B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities USD 2.77B 2024-01-01 2024-06-30 2025 Q2 6-K 2025-07-29 0001104659-25-071432
ifrs-full CashOutflowForLeases CashOutflowForLeases USD 452.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CashTransferred CashTransferred USD 1.50B 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full ChangesInEquity ChangesInEquity USD 7.85B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ClosingForeignExchangeRate ClosingForeignExchangeRate CNY/USD 6.68 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full ComprehensiveIncome ComprehensiveIncome USD 12.94B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ComprehensiveIncomeAttributableToNoncontrollingInterests ComprehensiveIncomeAttributableToNoncontrollingInterests USD 16.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ComprehensiveIncomeAttributableToOwnersOfParent ComprehensiveIncomeAttributableToOwnersOfParent USD 12.92B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ContingentLiabilitiesRecognisedInBusinessCombination ContingentLiabilitiesRecognisedInBusinessCombination USD 550.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ContractualCapitalCommitments ContractualCapitalCommitments USD 1.73B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CostOfInventoriesRecognisedAsExpenseDuringPeriod CostOfInventoriesRecognisedAsExpenseDuringPeriod USD 7.60B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CostOfSales CostOfSales USD 10.63B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentAccruedIncomeOtherThanCurrentContractAssets CurrentAccruedIncomeOtherThanCurrentContractAssets USD 844.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentAssets CurrentAssets USD 28.72B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings USD 3.10B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentContractLiabilities CurrentContractLiabilities USD 12.00M 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full CurrentDerivativeFinancialAssets CurrentDerivativeFinancialAssets USD 90.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentDerivativeFinancialLiabilities CurrentDerivativeFinancialLiabilities USD 81.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentFinanceLeaseLiabilities CurrentFinanceLeaseLiabilities USD 5.00M 2017-12-31 2018 Q2 6-K 2018-07-26 0001104659-18-047274
ifrs-full CurrentFinancialAssetsAtFairValueThroughProfitOrLoss CurrentFinancialAssetsAtFairValueThroughProfitOrLoss USD 8.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentFinancialAssetsAvailableforsale CurrentFinancialAssetsAvailableforsale USD 1.15B 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full CurrentGovernmentGrants CurrentGovernmentGrants USD 2.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentInvestments CurrentInvestments USD 30.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentLeaseLiabilities CurrentLeaseLiabilities USD 382.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentLiabilities CurrentLiabilities USD 30.62B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax USD 580.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentPortionOfLongtermBorrowings CurrentPortionOfLongtermBorrowings USD 4.46B 2025-06-30 2025 Q2 6-K 2025-07-29 0001104659-25-071432
ifrs-full CurrentPrepayments CurrentPrepayments USD 2.03B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentProvisions CurrentProvisions USD 686.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentRawMaterialsAndCurrentProductionSupplies CurrentRawMaterialsAndCurrentProductionSupplies USD 1.86B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived USD 0 2023-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full CurrentServiceCostDefinedBenefitPlans CurrentServiceCostDefinedBenefitPlans USD 86.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxAssets CurrentTaxAssets USD 2.55B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxAssetsCurrent CurrentTaxAssetsCurrent USD 1.16B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxAssetsNoncurrent CurrentTaxAssetsNoncurrent USD 1.39B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxExpenseIncome CurrentTaxExpenseIncome USD 2.42B 2023-01-01 2023-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods USD 2.33B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes USD 194.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxLiabilities CurrentTaxLiabilities USD 1.78B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxLiabilitiesCurrent CurrentTaxLiabilitiesCurrent USD 1.08B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTaxLiabilitiesNoncurrent CurrentTaxLiabilitiesNoncurrent USD 700.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full CurrentTradeReceivables CurrentTradeReceivables USD 10.24B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsOtherThanGoodwill DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsOtherThanGoodwill USD 1.50B 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised USD 719.00M 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full DeferredTaxAssets DeferredTaxAssets USD 5.82B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset USD 15.00M 2021-01-01 2021-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full DeferredTaxExpenseIncomeRecognisedInProfitOrLoss DeferredTaxExpenseIncomeRecognisedInProfitOrLoss USD -164.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences USD -117.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DeferredTaxLiabilities DeferredTaxLiabilities USD 3.50B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DeferredTaxLiabilityAsset DeferredTaxLiabilityAsset USD -2.32B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity USD -105.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DefinedBenefitObligationAtPresentValue DefinedBenefitObligationAtPresentValue USD 7.48B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss USD 5.48B 2022-01-01 2022-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full DepreciationPropertyPlantAndEquipment DepreciationPropertyPlantAndEquipment USD 879.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DepreciationRightofuseAssets DepreciationRightofuseAssets USD 404.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DerivativeFinancialAssets DerivativeFinancialAssets USD 145.00M 2021-06-30 2021 Q2 6-K 2021-07-30 0001104659-21-097781
ifrs-full DerivativesAmountContributedToFairValueOfPlanAssets DerivativesAmountContributedToFairValueOfPlanAssets USD -355.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets USD 0 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DilutedEarningsLossPerShare DilutedEarningsLossPerShare USD/shares 6.54 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares shares 12.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DistributionCosts DistributionCosts USD 579.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsPaidClassifiedAsFinancingActivities DividendsPaidClassifiedAsFinancingActivities USD 4.97B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsPaidOrdinaryShares DividendsPaidOrdinaryShares USD 4.85B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsPaidOrdinarySharesPerShare DividendsPaidOrdinarySharesPerShare USD/shares 1.03 2025-09-08 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsRecognisedAsDistributionsToNoncontrollingInterests DividendsRecognisedAsDistributionsToNoncontrollingInterests USD 6.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsRecognisedAsDistributionsToOwnersOfParent DividendsRecognisedAsDistributionsToOwnersOfParent USD 4.85B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear USD 1.60B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears USD 3.25B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full DividendsRecognisedAsDistributionsToOwnersPerShare DividendsRecognisedAsDistributionsToOwnersPerShare USD/shares 3.13 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full EffectOfExchangeRateChangesOnCashAndCashEquivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents USD 46.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full EmployeeBenefitsExpense EmployeeBenefitsExpense USD 14.55B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Equity Equity USD 48.72B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full EquityAttributableToOwnersOfParent EquityAttributableToOwnersOfParent USD 48.67B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets USD 615.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full ExpenseFromSharebasedPaymentTransactionsWithEmployees ExpenseFromSharebasedPaymentTransactionsWithEmployees USD 719.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ExpenseOfRestructuringActivities ExpenseOfRestructuringActivities USD 237.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed USD 1.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed USD 4.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities USD 4.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full FinanceCosts FinanceCosts USD 1.69B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinanceIncome FinanceIncome USD 360.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinanceIncomeCost FinanceIncomeCost USD -1.33B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinancialAssets FinancialAssets USD 6.39B 2022-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full FinancialAssetsAtFairValueThroughProfitOrLoss FinancialAssetsAtFairValueThroughProfitOrLoss USD 19.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinancialAssetsAvailableforsale FinancialAssetsAvailableforsale USD 2.08B 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome USD 2.21B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets USD 63.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities USD 63.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full FinancialLiabilities FinancialLiabilities USD 30.30B 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full FinancialLiabilitiesAtAmortisedCost FinancialLiabilitiesAtAmortisedCost USD 2.15B 2019-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full FinancialLiabilitiesAtFairValue FinancialLiabilitiesAtFairValue USD 29.18B 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full FinishedGoods FinishedGoods USD 1.92B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GainsLossesOnAvailableforsaleFinancialAssets GainsLossesOnAvailableforsaleFinancialAssets USD 34.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full GainsLossesOnCashFlowHedgesBeforeTax GainsLossesOnCashFlowHedgesBeforeTax USD 263.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GainsLossesOnChangeInFairValueOfDerivatives GainsLossesOnChangeInFairValueOfDerivatives USD -4.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full GainsLossesOnDisposalsOfNoncurrentAssets GainsLossesOnDisposalsOfNoncurrentAssets USD 25.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full GainsLossesOnDisposalsOfOtherNoncurrentAssets GainsLossesOnDisposalsOfOtherNoncurrentAssets USD 25.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss USD -218.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax USD 40.00M 2023-01-01 2023-06-30 2023 Q2 6-K 2023-07-28 0001104659-23-085104
ifrs-full GainsLossesOnIneffectivenessOfCashFlowHedgesRecognisedInProfitOrLoss GainsLossesOnIneffectivenessOfCashFlowHedgesRecognisedInProfitOrLoss USD 0 2017-01-01 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full GainsOnChangeInFairValueOfDerivatives GainsOnChangeInFairValueOfDerivatives USD 113.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GainsOnDisposalsOfInvestments GainsOnDisposalsOfInvestments USD 161.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full Goodwill Goodwill USD 21.24B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GoodwillDerecognisedWithoutHavingPreviouslyBeenIncludedInDisposalGroupClassifiedAsHeldForSale GoodwillDerecognisedWithoutHavingPreviouslyBeenIncludedInDisposalGroupClassifiedAsHeldForSale USD 603.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements USD 610.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements USD 554.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full GrossProfit GrossProfit USD 48.11B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ImpairmentLossOnFinancialAssets ImpairmentLossOnFinancialAssets USD 14.00M 2017-01-01 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full ImpairmentLossRecognisedInProfitOrLossGoodwill ImpairmentLossRecognisedInProfitOrLossGoodwill USD 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill USD 230.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment USD 13.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ImpairmentLossRecognisedInProfitOrLossRightofuseAssets ImpairmentLossRecognisedInProfitOrLossRightofuseAssets USD 7.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeFromSubleasingRightofuseAssets IncomeFromSubleasingRightofuseAssets USD 3.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full IncomeTaxesPaidRefund IncomeTaxesPaidRefund USD 2.75B 2024-01-01 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full IncomeTaxesPaidRefundClassifiedAsOperatingActivities IncomeTaxesPaidRefundClassifiedAsOperatingActivities USD 2.85B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxExpenseContinuingOperations IncomeTaxExpenseContinuingOperations USD 2.17B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome USD -2.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome USD -16.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome USD 91.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss USD 50.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss USD 94.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome USD -57.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full IncomeTaxRelatingToHedgesOfNetInvestmentsInForeignOperationsOfOtherComprehensiveIncome IncomeTaxRelatingToHedgesOfNetInvestmentsInForeignOperationsOfOtherComprehensiveIncome USD 66.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome USD 25.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncomeTaxRelatingToOtherIndividuallyImmaterialComponentsOfOtherComprehensiveIncome IncomeTaxRelatingToOtherIndividuallyImmaterialComponentsOfOtherComprehensiveIncome USD -1.00M 2016-01-01 2016-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome USD 69.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRate IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRate USD -195.00M 2021-01-01 2021-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges USD 223.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseInDeferredTaxLiabilityAsset IncreaseDecreaseInDeferredTaxLiabilityAsset USD -277.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseInExistingProvisionsOtherProvisions IncreaseDecreaseInExistingProvisionsOtherProvisions USD 698.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseInNetDefinedBenefitLiabilityAsset IncreaseDecreaseInNetDefinedBenefitLiabilityAsset USD -64.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full IncreaseDecreaseInNumberOfSharesOutstanding IncreaseDecreaseInNumberOfSharesOutstanding shares 907,239 2019-01-01 2019-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset USD 4.17B 2021-01-01 2021-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination USD -112.00M 2021-01-01 2021-06-30 2021 Q2 6-K 2021-07-30 0001104659-21-097781
ifrs-full IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl USD -257.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities USD 692.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities USD -2.02B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset USD -99.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions USD 122.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities USD 12.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities USD 138.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughSharebasedPaymentTransactions IncreaseDecreaseThroughSharebasedPaymentTransactions USD 719.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions USD 258.00M 2020-01-01 2020-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full IncreaseDecreaseThroughTreasuryShareTransactions IncreaseDecreaseThroughTreasuryShareTransactions USD 43.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseThroughAdjustmentsArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination IncreaseThroughAdjustmentsArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination USD 60.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities USD 566.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IntangibleAssetsOtherThanGoodwill IntangibleAssetsOtherThanGoodwill USD 37.85B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestCostsCapitalised InterestCostsCapitalised USD 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestExpenseDefinedBenefitPlans InterestExpenseDefinedBenefitPlans USD 340.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestExpenseIncomeDefinedBenefitPlans InterestExpenseIncomeDefinedBenefitPlans USD 51.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestExpenseOnBankLoansAndOverdrafts InterestExpenseOnBankLoansAndOverdrafts USD 74.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full InterestExpenseOnBorrowings InterestExpenseOnBorrowings USD 1.33B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestExpenseOnDebtInstrumentsIssued InterestExpenseOnDebtInstrumentsIssued USD 700.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full InterestExpenseOnLeaseLiabilities InterestExpenseOnLeaseLiabilities USD 80.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestIncomeDefinedBenefitPlans InterestIncomeDefinedBenefitPlans USD 289.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestIncomeOnDeposits InterestIncomeOnDeposits USD 11.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full InterestIncomeOnLoansAndReceivables InterestIncomeOnLoansAndReceivables USD 3.00M 2022-01-01 2022-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full InterestPaidClassifiedAsOperatingActivities InterestPaidClassifiedAsOperatingActivities USD 1.32B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InterestReceivedClassifiedAsInvestingActivities InterestReceivedClassifiedAsInvestingActivities USD 286.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Inventories Inventories USD 6.56B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InventoryWritedown2011 InventoryWritedown2011 USD 664.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full InvestmentAccountedForUsingEquityMethod InvestmentAccountedForUsingEquityMethod USD 302.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full InvestmentsInSubsidiariesJointVenturesAndAssociates InvestmentsInSubsidiariesJointVenturesAndAssociates USD 157.00M 2018-06-30 2018 Q2 6-K 2018-07-26 0001104659-18-047274
ifrs-full IssuedCapital IssuedCapital USD 388.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full IssueOfEquity IssueOfEquity USD 40.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full KeyManagementPersonnelCompensation KeyManagementPersonnelCompensation USD 99.39M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full KeyManagementPersonnelCompensationPostemploymentBenefits KeyManagementPersonnelCompensationPostemploymentBenefits USD 995,000 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full KeyManagementPersonnelCompensationSharebasedPayment KeyManagementPersonnelCompensationSharebasedPayment USD 58.91M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full KeyManagementPersonnelCompensationShorttermEmployeeBenefits KeyManagementPersonnelCompensationShorttermEmployeeBenefits USD 39.48M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full LeaseAndSubleasePaymentsRecognisedAsExpense LeaseAndSubleasePaymentsRecognisedAsExpense USD 188.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full LeaseLiabilities LeaseLiabilities USD 1.80B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full Liabilities Liabilities USD 65.36B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full LiabilitiesArisingFromFinancingActivities LiabilitiesArisingFromFinancingActivities USD 29.62B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full LongtermBorrowings LongtermBorrowings USD 24.71B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full LossesOnChangeInFairValueOfDerivatives LossesOnChangeInFairValueOfDerivatives USD 49.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full MergerReserve MergerReserve USD 448.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease USD 684.00M 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full MiscellaneousOtherOperatingExpense MiscellaneousOtherOperatingExpense USD 68.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full MiscellaneousOtherOperatingIncome MiscellaneousOtherOperatingIncome USD 406.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full NetAssetsLiabilities NetAssetsLiabilities USD 48.72B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetDebt NetDebt USD 23.37B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetDeferredTaxAssets NetDeferredTaxAssets USD 8.00B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetDeferredTaxLiabilities NetDeferredTaxLiabilities USD 5.68B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements USD 82.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements USD 26.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NetForeignExchangeGain NetForeignExchangeGain USD 8.00M 2016-01-01 2016-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full NetForeignExchangeLoss NetForeignExchangeLoss USD 31.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination USD 198.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncontrollingInterests NoncontrollingInterests USD 52.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentAccruedIncome NoncurrentAccruedIncome USD 56.00M 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets USD 75.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentAssets NoncurrentAssets USD 85.35B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners USD 0 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts USD 74.42B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentContractLiabilities NoncurrentContractLiabilities USD 7.00M 2023-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full NoncurrentDerivativeFinancialAssets NoncurrentDerivativeFinancialAssets USD 498.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentDerivativeFinancialLiabilities NoncurrentDerivativeFinancialLiabilities USD 115.00M 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentFinancialAssets NoncurrentFinancialAssets USD 1.17B 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome USD 1.17B 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full NoncurrentFinancialAssetsAvailableforsale NoncurrentFinancialAssetsAvailableforsale USD 933.00M 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full NoncurrentGovernmentGrants NoncurrentGovernmentGrants USD 55.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod USD 2.22B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentLeaseLiabilities NoncurrentLeaseLiabilities USD 1.42B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentLiabilities NoncurrentLiabilities USD 34.74B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentPayables NoncurrentPayables USD 2.38B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentPortionOfNoncurrentSecuredBankLoansReceived NoncurrentPortionOfNoncurrentSecuredBankLoansReceived USD 0 2023-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full NoncurrentPrepayments NoncurrentPrepayments USD 559.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentProvisions NoncurrentProvisions USD 918.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentRecognisedAssetsDefinedBenefitPlan NoncurrentRecognisedAssetsDefinedBenefitPlan USD 106.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NoncurrentRecognisedLiabilitiesDefinedBenefitPlan NoncurrentRecognisedLiabilitiesDefinedBenefitPlan USD 1.10B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NumberOfEmployees NumberOfEmployees employee 96,100 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full NumberOfInstrumentsOtherEquityInstrumentsGranted NumberOfInstrumentsOtherEquityInstrumentsGranted shares 267,000 2023-01-01 2023-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherAdjustmentsForNoncashItems OtherAdjustmentsForNoncashItems USD 662.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherAssetsAmountContributedToFairValueOfPlanAssets OtherAssetsAmountContributedToFairValueOfPlanAssets USD 251.00M 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities USD 5.00M 2022-01-01 2022-06-30 2022 Q2 6-K 2022-07-29 0001104659-22-083922
ifrs-full OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities USD 10.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities USD 776.00M 2021-01-01 2021-06-30 2021 Q2 6-K/A 2021-07-30 0001104659-21-097940
ifrs-full OtherComprehensiveIncome OtherComprehensiveIncome USD 2.70B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeBeforeTaxAvailableforsaleFinancialAssets OtherComprehensiveIncomeBeforeTaxAvailableforsaleFinancialAssets USD -83.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full OtherComprehensiveIncomeBeforeTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability OtherComprehensiveIncomeBeforeTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability USD 12.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation USD 2.39B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeBeforeTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome OtherComprehensiveIncomeBeforeTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome USD 0 2018-01-01 2018-06-30 2018 Q2 6-K 2018-07-26 0001104659-18-047274
ifrs-full OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments USD 188.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans USD 290.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations USD 14.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets USD 0 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax USD 2.32B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax USD 384.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherCurrentPayables OtherCurrentPayables USD 1.67B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherCurrentReceivables OtherCurrentReceivables USD 2.02B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherEmployeeExpense OtherEmployeeExpense USD 1.61B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities USD 161.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities USD 131.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherNoncurrentPayables OtherNoncurrentPayables USD 2.04B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherNoncurrentReceivables OtherNoncurrentReceivables USD 1.33B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherOperatingIncomeExpense OtherOperatingIncomeExpense USD 381.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full OtherProvisions OtherProvisions USD 1.72B 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full OtherReserves OtherReserves USD 2.07B 2025-06-30 2025 Q2 6-K 2025-07-29 0001104659-25-071432
ifrs-full OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome USD -360.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ParValuePerShare ParValuePerShare USD/shares 0.25 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PastServiceCostDefinedBenefitPlans PastServiceCostDefinedBenefitPlans USD -26.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PaymentsFromChangesInOwnershipInterestsInSubsidiaries PaymentsFromChangesInOwnershipInterestsInSubsidiaries USD 183.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities USD 14.00M 2017-01-01 2017-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities USD 372.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PaymentsToAcquireOrRedeemEntitysShares PaymentsToAcquireOrRedeemEntitysShares USD 521.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PercentageOfReasonablyPossibleDecreaseInActuarialAssumption PercentageOfReasonablyPossibleDecreaseInActuarialAssumption pure 0.005 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full PercentageOfReasonablyPossibleIncreaseInActuarialAssumption PercentageOfReasonablyPossibleIncreaseInActuarialAssumption pure 0.005 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full PlanAssetsAtFairValue PlanAssetsAtFairValue USD 6.48B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PostemploymentBenefitExpenseDefinedBenefitPlans PostemploymentBenefitExpenseDefinedBenefitPlans USD 116.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PostemploymentBenefitExpenseDefinedContributionPlans PostemploymentBenefitExpenseDefinedContributionPlans USD 553.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PostemploymentBenefitExpenseInProfitOrLoss PostemploymentBenefitExpenseInProfitOrLoss USD 618.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromBorrowingsClassifiedAsFinancingActivities ProceedsFromBorrowingsClassifiedAsFinancingActivities USD 15.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromIssuingShares ProceedsFromIssuingShares USD 40.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities USD 78.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities USD 136.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod USD 13.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities USD 13.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLoss ProfitLoss USD 10.23B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLossAttributableToNoncontrollingInterests ProfitLossAttributableToNoncontrollingInterests USD 8.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity USD 10.22B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLossAttributableToOwnersOfParent ProfitLossAttributableToOwnersOfParent USD 10.22B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLossBeforeTax ProfitLossBeforeTax USD 12.40B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProfitLossFromOperatingActivities ProfitLossFromOperatingActivities USD 13.74B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PropertyPlantAndEquipment PropertyPlantAndEquipment USD 12.96B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProportionOfVotingPowerHeldInAssociate ProportionOfVotingPowerHeldInAssociate pure 0.29 2019-10-08 2019 FY 20-F 2020-03-03 0001104659-20-028557
ifrs-full Provisions Provisions USD 1.60B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ProvisionUsedOtherProvisions ProvisionUsedOtherProvisions USD 1.25B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities USD 3.10B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod USD 140.00M 2024-01-01 2024-06-30 2025 Q2 6-K 2025-07-29 0001104659-25-071432
ifrs-full PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities USD 229.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities USD 2.81B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full PurchaseOfTreasuryShares PurchaseOfTreasuryShares USD 0 2013-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsNetOfTax ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsNetOfTax USD -4.00M 2017-01-01 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax USD 314.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RecognisedAssetsDefinedBenefitPlan RecognisedAssetsDefinedBenefitPlan USD 99.00M 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full RecognisedLiabilitiesDefinedBenefitPlan RecognisedLiabilitiesDefinedBenefitPlan USD 1.33B 2024-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full RepaymentsOfBondsNotesAndDebentures RepaymentsOfBondsNotesAndDebentures USD 2.57B 2024-04-01 2024-06-30 2024 Q2 6-K 2024-07-25 0001104659-24-082531
ifrs-full RepaymentsOfBorrowingsClassifiedAsFinancingActivities RepaymentsOfBorrowingsClassifiedAsFinancingActivities USD 2.03B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ResearchAndDevelopmentExpense ResearchAndDevelopmentExpense USD 14.23B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReserveOfExchangeDifferencesOnTranslation ReserveOfExchangeDifferencesOnTranslation USD 0 2003-01-01 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full ReserveOfExchangeDifferencesOnTranslationHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied ReserveOfExchangeDifferencesOnTranslationHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied USD 527.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RestrictedCashAndCashEquivalents RestrictedCashAndCashEquivalents USD 236.00M 2022-06-30 2022 Q2 6-K 2022-07-29 0001104659-22-083922
ifrs-full RetainedEarnings RetainedEarnings USD 10.97B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseBeforeTaxDefinedBenefitPlans ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseBeforeTaxDefinedBenefitPlans USD 85.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset USD 932.00M 2019-01-01 2019-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full Revenue Revenue USD 58.74B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RevenueFromContractsWithCustomers RevenueFromContractsWithCustomers USD 36.54B 2021-01-01 2021-12-31 2021 FY 20-F 2022-02-22 0001104659-22-025720
ifrs-full RevenueFromGovernmentGrants RevenueFromGovernmentGrants USD 222.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-02-16 0001104659-21-022456
ifrs-full RevenueFromSaleOfGoods RevenueFromSaleOfGoods USD 55.57B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod USD 107.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReversalOfImpairmentLoss ReversalOfImpairmentLoss USD 28.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill USD 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ReversedUnsettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination ReversedUnsettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination USD 121.00M 2022-01-01 2022-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed USD 22.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RightofuseAssets RightofuseAssets USD 1.74B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full RoyaltyExpense RoyaltyExpense USD 4.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full SellingGeneralAndAdministrativeExpense SellingGeneralAndAdministrativeExpense USD 19.93B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination USD 1.16B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod USD -7.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full SharePremium SharePremium USD 35.27B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates shares 147,547 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ShorttermDepositsClassifiedAsCashEquivalents ShorttermDepositsClassifiedAsCashEquivalents USD 4.38B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full ShorttermDepositsNotClassifiedAsCashEquivalents ShorttermDepositsNotClassifiedAsCashEquivalents USD 64.00M 2022-12-31 2024 FY 20-F 2025-02-18 0001104659-25-014750
ifrs-full ShorttermInvestmentsClassifiedAsCashEquivalents ShorttermInvestmentsClassifiedAsCashEquivalents USD 1.15B 2017-12-31 2017 FY 20-F 2018-03-06 0001104659-18-015257
ifrs-full SocialSecurityContributions SocialSecurityContributions USD 1.35B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full SurplusDeficitInPlan SurplusDeficitInPlan USD -999.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense USD 105.00M 2017-01-01 2017-12-31 2018 FY 20-F 2019-03-05 0001104659-19-012881
ifrs-full TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense USD 22.00M 2020-01-01 2020-12-31 2022 FY 20-F 2023-02-21 0001104659-23-023818
ifrs-full TaxEffectFromChangeInTaxRate TaxEffectFromChangeInTaxRate USD -23.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss USD 101.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TaxEffectOfForeignTaxRates TaxEffectOfForeignTaxRates USD -168.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TaxEffectOfRevenuesExemptFromTaxation2011 TaxEffectOfRevenuesExemptFromTaxation2011 USD 163.00M 2021-01-01 2021-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553
ifrs-full TaxEffectOfTaxLosses TaxEffectOfTaxLosses USD 86.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TaxExpenseIncomeAtApplicableTaxRate TaxExpenseIncomeAtApplicableTaxRate USD 3.10B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures USD 8.46B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TerminationBenefitsExpense TerminationBenefitsExpense USD 190.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TradeAndOtherCurrentPayables TradeAndOtherCurrentPayables USD 25.28B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TradeAndOtherCurrentPayablesToTradeSuppliers TradeAndOtherCurrentPayablesToTradeSuppliers USD 3.82B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TradeAndOtherCurrentReceivables TradeAndOtherCurrentReceivables USD 15.18B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TradingIncomeExpenseOnForeignExchangeContracts TradingIncomeExpenseOnForeignExchangeContracts USD 190.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full TreasuryShares TreasuryShares USD 25.00M 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full UndrawnBorrowingFacilities UndrawnBorrowingFacilities USD 4.88B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full UnusedProvisionReversedOtherProvisions UnusedProvisionReversedOtherProvisions USD 157.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full WagesAndSalaries WagesAndSalaries USD 10.97B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full WeightedAverageShares WeightedAverageShares shares 1.55B 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full WorkInProgress WorkInProgress USD 2.78B 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full WritedownsReversalsOfInventories WritedownsReversalsOfInventories USD 314.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-02-24 0001104659-26-019130
ifrs-full WritedownsReversalsOfPropertyPlantAndEquipment WritedownsReversalsOfPropertyPlantAndEquipment USD 343.00M 2021-01-01 2021-12-31 2023 FY 20-F 2024-02-20 0001104659-24-025553

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →